Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial have?
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial has 447 citations in the OpenAlex counts ScholarIQ stores.
When was Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial published?
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial has 2014 year in the ScholarIQ index.
What is the open-access status of Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial?
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial has closed oa status in the ScholarIQ index.
What is the DOI of Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial?
The DOI for Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial is on the source record.
What is the PMID of Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial?
The PMID for Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial is on the source record.
What is the OpenAlex record for Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial?
The OpenAlex for Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial is on the source record.